BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 37150829)

  • 21. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell.
    Plouffe SW; Lin KC; Moore JL; Tan FE; Ma S; Ye Z; Qiu Y; Ren B; Guan KL
    J Biol Chem; 2018 Jul; 293(28):11230-11240. PubMed ID: 29802201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. YAP and TAZ Negatively Regulate Prox1 During Developmental and Pathologic Lymphangiogenesis.
    Cho H; Kim J; Ahn JH; Hong YK; Mäkinen T; Lim DS; Koh GY
    Circ Res; 2019 Jan; 124(2):225-242. PubMed ID: 30582452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor.
    Valencia-Sama I; Zhao Y; Lai D; Janse van Rensburg HJ; Hao Y; Yang X
    J Biol Chem; 2015 Jul; 290(27):16906-17. PubMed ID: 25995450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma.
    Hiemer SE; Zhang L; Kartha VK; Packer TS; Almershed M; Noonan V; Kukuruzinska M; Bais MV; Monti S; Varelas X
    Mol Cancer Res; 2015 Jun; 13(6):957-68. PubMed ID: 25794680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Yap and Taz regulate retinal pigment epithelial cell fate.
    Miesfeld JB; Gestri G; Clark BS; Flinn MA; Poole RJ; Bader JR; Besharse JC; Wilson SW; Link BA
    Development; 2015 Sep; 142(17):3021-32. PubMed ID: 26209646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of a Gene Signature That Predicts Dependence upon YAP/TAZ-TEAD.
    Kanai R; Norton E; Stern P; Hynes RO; Lamar JM
    Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative Real-Time PCR to Measure YAP/TAZ Activity in Human Cells.
    Cao X; Zhao B
    Methods Mol Biol; 2019; 1893():137-152. PubMed ID: 30565132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment of transgenic lines to monitor and manipulate Yap/Taz-Tead activity in zebrafish reveals both evolutionarily conserved and divergent functions of the Hippo pathway.
    Miesfeld JB; Link BA
    Mech Dev; 2014 Aug; 133():177-88. PubMed ID: 24560909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.
    Shreberk-Shaked M; Dassa B; Sinha S; Di Agostino S; Azuri I; Mukherjee S; Aylon Y; Blandino G; Ruppin E; Oren M
    Cancer Res; 2020 Oct; 80(19):4145-4157. PubMed ID: 32816858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
    Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
    Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
    Hagenbeek TJ; Zbieg JR; Hafner M; Mroue R; Lacap JA; Sodir NM; Noland CL; Afghani S; Kishore A; Bhat KP; Yao X; Schmidt S; Clausen S; Steffek M; Lee W; Beroza P; Martin S; Lin E; Fong R; Di Lello P; Kubala MH; Yang MN; Lau JT; Chan E; Arrazate A; An L; Levy E; Lorenzo MN; Lee HJ; Pham TH; Modrusan Z; Zang R; Chen YC; Kabza M; Ahmed M; Li J; Chang MT; Maddalo D; Evangelista M; Ye X; Crawford JJ; Dey A
    Nat Cancer; 2023 Jun; 4(6):812-828. PubMed ID: 37277530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interrogating the precancerous evolution of pathway dysfunction in lung squamous cell carcinoma using XTABLE.
    Roberts M; Ogden J; Hossain ASM; Chaturvedi A; Kerr ARW; Dive C; Beane JE; Lopez-Garcia C
    Elife; 2023 Mar; 12():. PubMed ID: 36892933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Common and Distinctive Functions of the Hippo Effectors Taz and Yap in Skeletal Muscle Stem Cell Function.
    Sun C; De Mello V; Mohamed A; Ortuste Quiroga HP; Garcia-Munoz A; Al Bloshi A; Tremblay AM; von Kriegsheim A; Collie-Duguid E; Vargesson N; Matallanas D; Wackerhage H; Zammit PS
    Stem Cells; 2017 Aug; 35(8):1958-1972. PubMed ID: 28589555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of Quinolinols as Activators of TEAD-Dependent Transcription.
    Pobbati AV; Mejuch T; Chakraborty S; Karatas H; Bharath SR; Guéret SM; Goy PA; Hahne G; Pahl A; Sievers S; Guccione E; Song H; Waldmann H; Hong W
    ACS Chem Biol; 2019 Dec; 14(12):2909-2921. PubMed ID: 31742995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic targeting of TEAD transcription factors in cancer.
    Pobbati AV; Kumar R; Rubin BP; Hong W
    Trends Biochem Sci; 2023 May; 48(5):450-462. PubMed ID: 36709077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation.
    Canu V; Donzelli S; Sacconi A; Lo Sardo F; Pulito C; Bossel N; Di Benedetto A; Muti P; Botti C; Domany E; Bicciato S; Strano S; Yarden Y; Blandino G
    Cell Death Differ; 2021 May; 28(5):1493-1511. PubMed ID: 33230261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Hippo Pathway Effectors YAP/TAZ-TEAD Oncoproteins as Emerging Therapeutic Targets in the Tumor Microenvironment.
    Mokhtari RB; Ashayeri N; Baghaie L; Sambi M; Satari K; Baluch N; Bosykh DA; Szewczuk MR; Chakraborty S
    Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
    Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
    Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions.
    Beane JE; Mazzilli SA; Campbell JD; Duclos G; Krysan K; Moy C; Perdomo C; Schaffer M; Liu G; Zhang S; Liu H; Vick J; Dhillon SS; Platero SJ; Dubinett SM; Stevenson C; Reid ME; Lenburg ME; Spira AE
    Nat Commun; 2019 Apr; 10(1):1856. PubMed ID: 31015447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.